NewLink Genetics, Merck collaboration to manufacture Ebola vaccine candidate
NewLink Genetics and Merck announced that BARDA has awarded NewLink Genetics' wholly-owned subsidiary, BioProtection Systems, as the prime contractor in a $30 million contract to support manufacturing and development activities of its investigational rVSV-EBOV (Ebola) vaccine candidate. December 22, 2014